Seres Therapeutics
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $64 |
Gross Profit | -1,420 | -1,559 | -3,989 | |
EBITDA | -29,170 | -28,003 | -33,911 | -33,166 |
EBIT | -30,574 | -29,423 | -35,470 | -37,219 |
Net Income | 88,776 | -32,869 | -40,133 | -41,248 |
Net Change In Cash | 0 | 0 | 0 | 64 |
Free Cash Flow | -34,809 | -39,910 | -35,298 | -48,376 |
Cash | 66,824 | 71,232 | 111,184 | 127,965 |
Basic Shares | 152,648 | 151,514 | 146,101 | 129,262 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $126,325 | $7,128 | $144,927 | $33,215 |
Gross Profit | 125,621 | 6,124 | 143,195 | -57,355 |
EBITDA | -85,434 | -237,508 | -56,721 | -77,310 |
EBIT | -100,548 | -249,361 | -65,943 | -86,203 |
Net Income | -113,724 | -253,824 | -61,496 | -86,454 |
Net Change In Cash | 126,325 | 7,128 | 144,927 | 33,215 |
Cost of Revenue | -16,786 | 71,954 | 50,923 | |
Free Cash Flow | -125,329 | -238,637 | -2,878 | -94,201 |
Cash | 127,965 | 163,030 | 180,002 | 116,049 |
Basic Shares | 128,003 | 108,077 | 91,702 | 79,789 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.33 |
2024-06-30 | -$0.22 |
2024-03-31 | -$0.27 |
2023-12-31 | -$0.32 |
